List of Excipients in Branded Drug CALCIUM GLUCONATE IN SODIUM CHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
WG Critical Care LLC	CALCIUM GLUCONATE IN SODIUM CHLORIDE	calcium gluconate	44567-620	CALCIUM SACCHARATE
WG Critical Care LLC	CALCIUM GLUCONATE IN SODIUM CHLORIDE	calcium gluconate	44567-620	HYDROCHLORIC ACID
WG Critical Care LLC	CALCIUM GLUCONATE IN SODIUM CHLORIDE	calcium gluconate	44567-620	SODIUM CHLORIDE
WG Critical Care LLC	CALCIUM GLUCONATE IN SODIUM CHLORIDE	calcium gluconate	44567-620	SODIUM HYDROXIDE

Calcium Gluconate in Sodium Chloride: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 8, 2026

Calcium Gluconate in Sodium Chloride Injection is a mature, largely off-patent sterile injectable. Its commercial value comes from ready-to-use hospital supply, reliable calcium delivery, shortage resilience, packaging performance, and manufacturing efficiency rather than from novel active-ingredient chemistry. The strongest product strategy is a preservative-free premix using sodium chloride injection as the vehicle, with differentiated concentrations, container systems, stability data, and dependable hospital distribution.

What is Calcium Gluconate in Sodium Chloride Injection?

Calcium Gluconate in Sodium Chloride Injection is an intravenous solution containing calcium gluconate in a sodium chloride vehicle. It is used when intravenous calcium replacement is clinically required, including acute symptomatic hypocalcemia and other hospital indications described in product labeling.

A typical formulation contains:

Component	Function
Calcium gluconate	Active pharmaceutical ingredient and source of elemental calcium
Sodium chloride	Isotonic vehicle and sodium/chloride source
Water for Injection	Solvent
pH adjusters, where used	Product pH control

Calcium gluconate contains approximately 9.3% elemental calcium by weight. A 1 g dose of calcium gluconate therefore provides approximately 93 mg of elemental calcium, subject to the specific formulation and labeling convention.[1]

The product is generally supplied as a sterile, preservative-free solution for intravenous administration. Concentrations can be expressed as calcium gluconate per milliliter or as elemental calcium per milliliter. That distinction is commercially important because clinical users may compare products using either metric.

What excipients are used in Calcium Gluconate in Sodium Chloride?

Sodium chloride is the principal functional excipient. A conventional 0.9% sodium chloride vehicle provides approximately 154 mEq/L each of sodium and chloride and is widely accepted for parenteral administration.

The excipient platform is intentionally narrow. Injectable calcium gluconate products generally have limited formulation latitude because additional excipients can create compatibility, toxicity, particulate, osmolality, and regulatory risks.

Core excipient strategy

A commercially viable formulation should prioritize:

1. Sodium chloride concentration consistent with the intended route and clinical setting.
2. Water for Injection meeting pharmacopeial requirements.
3. Controlled pH without unnecessary buffering.
4. Low particulate burden.
5. Low extractables and leachables from the container.
6. Compatibility with hospital infusion equipment.
7. Long refrigerated and room-temperature stability, where supported by data.

The main formulation challenge is maintaining calcium gluconate solubility and chemical stability while controlling pH, osmolality, container interaction, and precipitation risk. The product must also avoid interactions with phosphate-containing solutions, bicarbonate-containing solutions, and other incompatible drugs.

Why a minimal-excipient formulation is commercially preferable

A short excipient list reduces several development and manufacturing risks:

• Fewer extractables and leachables investigations.
• Lower risk of excipient-related adverse reactions.
• Simpler compendial and regulatory justification.
• Easier hospital formulary review.
• Lower raw-material and batch-release complexity.
• Reduced risk of incompatibility with infusion systems.

For this product, excipient innovation is less likely to create a legally protectable composition than a manufacturing, container, or delivery-system improvement.

What formulations are protected by Calcium Gluconate in Sodium Chloride products?

The most defensible differentiation is likely to come from formulation and presentation claims rather than from new calcium gluconate chemistry.

Potential formulation positions include:

Formulation or presentation	Commercial rationale	Patent potential
Low-concentration ready-to-use bag	Emergency departments and general inpatient use	Limited unless stability or container technology is novel
High-concentration premix	ICU and controlled infusion settings	Moderate only if supported by unusual stability or delivery technology
Small-volume bag or vial	Lower waste and lower storage burden	Limited
Non-PVC container	Specialty hospital and neonatal procurement	Possible container or compatibility claims
Low-extractables container	High-risk injectable procurement	Possible, but usually difficult to enforce broadly
Extended-stability presentation	Reduced inventory loss and wider distribution	Potentially stronger if data support a novel stability profile
Terminally sterilized product	Manufacturing and quality advantage	Process protection may be available
Single-dose syringe	Emergency response and bedside administration	Device and packaging claims may be available

The strongest defensible position is usually a combination of concentration, container, fill volume, sterilization method, and stability profile. A generic claim covering calcium gluconate in sodium chloride would face substantial prior-art and obviousness pressure.

How strong is the patent estate for Calcium Gluconate in Sodium Chloride?

The patent estate is weak from an active-ingredient perspective. Calcium gluconate is an old, well-established compound, and sodium chloride injection is a conventional parenteral vehicle. The product does not depend on a new molecular entity patent, a biologic patent, or a novel mechanism-of-action patent.

Patent categories that may still matter

Commercially relevant rights may arise in four areas:

• Sterile manufacturing processes.
• Container and closure systems.
• Long-term stability and preservative-free presentations.
• Integrated infusion devices or prefilled delivery systems.

These rights are narrower than composition-of-matter patents and may be easier to design around. A competitor could often enter with a different bag material, fill volume, sterilization process, or concentration if it can meet the same clinical and regulatory requirements.

What patent numbers protect the product?

No product-specific patent number is required to support the basic commercial formulation. The core formulation is based on established active and excipient materials, compendial standards, and FDA-approved sterile injectable manufacturing practices.

A transaction or freedom-to-operate review should focus on current U.S. patents covering:

• Multilayer infusion bags.
• Non-PVC films.
• Calcium-containing sterile solutions.
• Automated compounding and filling systems.
• Terminal sterilization processes.
• Prefilled syringes and administration sets.

The relevant commercial risk is likely to arise from packaging and manufacturing patents rather than from calcium gluconate or sodium chloride composition claims.

What is the FDA regulatory status of Calcium Gluconate in Sodium Chloride?

Calcium Gluconate in Sodium Chloride Injection is regulated as a prescription sterile injectable drug. The applicable regulatory requirements include current good manufacturing practice, sterile processing controls, container-closure integrity, particulate testing, sterility testing, endotoxin controls, assay, pH, osmolality where applicable, and stability studies under 21 C.F.R. Parts 210 and 211.[2]

The product may be marketed through an approved new drug application, an abbreviated new drug application, or another FDA-recognized pathway depending on the specific sponsor, formulation, concentration, and product history. Regulatory status must be evaluated at the individual product level because the presence of calcium gluconate products in the market does not automatically establish approval for every concentration or container configuration.

FDA development considerations

A new entrant should expect regulatory scrutiny over:

• Active-ingredient strength and elemental calcium equivalence.
• Route of administration.
• Concentration and fill volume.
• Solution clarity and visible particles.
• Container-closure integrity.
• Compatibility with administration sets.
• Calcium gluconate assay and impurities.
• Stability after dilution or transfer, if claimed.
• Labeling for administration rate and compatibility.
• Risk of medication error between calcium gluconate and calcium chloride.

Calcium chloride and calcium gluconate are not interchangeable on a milligram-for-milligram basis. Labeling must clearly distinguish the salt and elemental calcium content.

What is the Orange Book status of Calcium Gluconate in Sodium Chloride?

The basic product category is expected to have limited Orange Book exclusivity because calcium gluconate is an established generic active ingredient and the formulation is conventional. The relevant Orange Book analysis should identify:

• Listed reference products.
• Approved strengths and presentations.
• Patent listings under Section 505(b)(1).
• Pediatric exclusivity, if any.
• New chemical entity exclusivity.
• Three-year clinical investigation exclusivity.
• Six-month pediatric exclusivity.

No NCE exclusivity is expected for calcium gluconate. Any remaining protection would more likely involve a product-specific formulation, delivery system, or method of use. Generic applicants would normally evaluate Paragraph IV and Paragraph III certification obligations only if an Orange Book-listed patent applies to the reference product.[3]

When does Calcium Gluconate in Sodium Chloride lose exclusivity?

The active ingredient has no meaningful remaining composition-of-matter exclusivity. Commercial exclusivity therefore depends on the specific approved product and any listed patents or regulatory exclusivities associated with that product.

For a conventional calcium gluconate/sodium chloride injectable, the main barriers to entry are:

• FDA approval requirements.
• Sterile manufacturing capacity.
• Validated aseptic or terminal sterilization processes.
• Reliable supply of pharmaceutical-grade calcium gluconate.
• Container-closure qualification.
• Hospital contracting and distribution.
• Product liability and shortage-service expectations.

A competitor does not need to wait for an active-ingredient patent expiration if no enforceable patent covers the proposed product. Its launch timing would depend on approval, any applicable certifications, regulatory exclusivity, and commercial readiness.

What generic entry risks exist for Calcium Gluconate in Sodium Chloride?

Generic entry risk is high because the product has several characteristics associated with competitive substitution:

• Established active ingredient.
• Simple excipient platform.
• Familiar clinical use.
• Limited formulation novelty.
• Multiple potential sterile manufacturers.
• Low likelihood of meaningful active-ingredient patent protection.
• Hospital demand that can be met through standard injectable infrastructure.

The main constraint is manufacturing execution. Sterile injectable shortages can occur even in mature categories when a small number of facilities supply the market. A new entrant with a qualified facility and dependable supply can gain share quickly, particularly if incumbent products are unavailable or subject to allocation.

Generic launch scenarios

Scenario	Likely market effect
One additional approved supplier	Modest price and supply pressure
Multiple suppliers with standard bags	Increased contracting pressure and lower margins
New supplier during shortage	Rapid formulary adoption and premium for reliability
Non-PVC or low-extractables product	Selective uptake by hospitals with packaging preferences
Prefilled syringe or compact presentation	Share gain in emergency and procedural settings
High-concentration product	Niche adoption if dosing and administration risks are controlled

Which companies are challenging the commercial position of Calcium Gluconate products?

Competition is likely to come from generic sterile-injectable manufacturers, hospital-supply companies, and contract manufacturers rather than from branded pharmaceutical innovators.

Relevant competitor groups include:

• Large generic injectable manufacturers.
• Hospital injectable suppliers.
• Specialty sterile manufacturers.
• Contract development and manufacturing organizations.
• International suppliers seeking U.S. approval.
• Manufacturers with non-PVC infusion-bag platforms.

The most valuable competitive assets are FDA-inspected sterile capacity, validated calcium-containing formulations, ready access to infusion bags, and established group purchasing organization relationships.

What commercial opportunities exist for excipient and presentation innovation?

The strongest opportunities are operational and presentation-based.

Ready-to-use premixed bags

A ready-to-use bag eliminates bedside compounding and reduces preparation errors. Hospitals may value:

• Standardized concentration.
• Reduced pharmacy labor.
• Lower compounding exposure.
• Faster emergency administration.
• Better inventory control.

Non-PVC and low-extractables packaging

Non-PVC systems may be attractive in neonatal, pediatric, oncology, and specialty hospital settings. The commercial value depends on procurement requirements, compatibility data, and whether the container performs adequately under calcium-containing solution conditions.

Concentration segmentation

A supplier could develop a portfolio covering:

• General inpatient replacement.
• Emergency department use.
• ICU infusion.
• Pediatric or neonatal dosing.
• Small-volume procedural use.

The principal risk is medication error. Multiple concentrations increase inventory complexity and require prominent labeling, barcode controls, and clear elemental calcium information.

Prefilled syringes

Prefilled syringes can reduce preparation time and improve emergency-cart readiness. They create new device, human-factors, extractables, and stability requirements. Their economics work best where speed and reduced manipulation have a measurable operational value.

Supply-resilience contracts

Hospitals and group purchasing organizations may pay for dependable supply in mature injectable categories. A supplier with dual-source raw materials, redundant filling capacity, and validated alternative packaging can differentiate without relying on patent exclusivity.

What manufacturing and IP barriers affect market entry?

Manufacturing is the primary barrier. Calcium-containing sterile products require robust control of:

• Raw-material identity and purity.
• Solution preparation and mixing.
• pH and osmolality.
• Bioburden before sterilization.
• Sterility assurance.
• Particulates and precipitation.
• Container-closure integrity.
• Shipping and temperature excursions.
• Labeling and barcode accuracy.

The most credible IP strategy is a focused portfolio around:

1. A specific container composition.
2. A validated stability advantage.
3. A prefilled delivery device.
4. A manufacturing process that improves sterility assurance or yield.
5. A compatibility package covering administration sets or co-infusion conditions.

Broad composition claims are less likely to provide durable protection.

What licensing deals and settlement agreements affect the product?

The category does not require a licensing model comparable to a patented branded drug or biologic. Commercial agreements are more likely to involve:

• Contract manufacturing.
• Regional distribution.
• Infusion-bag technology.
• Private-label supply.
• Hospital or group purchasing contracts.
• Device-container partnerships.

Paragraph IV litigation and settlement agreements are not expected to be central to a conventional calcium gluconate/sodium chloride product unless a specific reference product has a currently listed formulation or device patent. The commercial focus should therefore remain on FDA approval, supply reliability, pricing, and account access.

How does Calcium Gluconate in Sodium Chloride compare with Calcium Chloride Injection?

Factor	Calcium gluconate in sodium chloride	Calcium chloride injection
Calcium salt	Calcium gluconate	Calcium chloride
Elemental calcium per gram	Lower	Higher
Typical use	Calcium replacement and controlled IV administration	More concentrated emergency calcium use
Tissue injury risk on extravasation	Generally lower than calcium chloride	Higher
Formulation opportunity	Premix, bags, syringes, concentration segmentation	Concentrated ampoules, syringes, emergency products
Patent position	Mature and largely generic	Mature and largely generic
Commercial differentiation	Packaging, stability, supply, convenience	Concentration, emergency readiness, device presentation

The two products compete clinically in some settings but are not direct substitutes by mass or elemental calcium content. Substitution decisions depend on indication, urgency, route, concentration, and institutional protocol.

Key Takeaways

• Calcium Gluconate in Sodium Chloride Injection is a mature sterile injectable with limited active-ingredient patent value.
• Sodium chloride is the central excipient and functional vehicle.
• The best formulation strategy uses a minimal excipient system with strong stability, compatibility, and container-closure data.
• The commercial opportunity is strongest in ready-to-use bags, non-PVC packaging, prefilled syringes, concentration segmentation, and shortage-resilient supply.
• Generic entry risk is high because the formulation is conventional and the active ingredient is old.
• Manufacturing capacity, sterility assurance, packaging performance, and hospital contracting are more important than composition-of-matter IP.
• Product-specific Orange Book, patent, and exclusivity analysis must be conducted at the individual reference-product level.
• Calcium gluconate should not be treated as dose-equivalent to calcium chloride because elemental calcium content and clinical risk profiles differ.

FAQs

Is sodium chloride an excipient in Calcium Gluconate Injection?

Yes. Sodium chloride functions primarily as the vehicle and tonicity-adjusting component. Water for Injection is the solvent, while pH adjustment may be performed when required by the formulation.

Can calcium gluconate be formulated in dextrose instead of sodium chloride?

A dextrose vehicle may be technically possible for some calcium products, but it would create a different formulation and regulatory product. Compatibility, stability, osmolality, labeling, and clinical-use data would need to support the alternative vehicle.

Does calcium gluconate injection have meaningful biologic or biosimilar risk?

No. Calcium gluconate is a small-molecule inorganic-organic salt, not a biologic. Biosimilar regulation does not apply. Competition occurs through generic drug approval and sterile injectable manufacturing.

What is the most defensible patent strategy for a calcium gluconate premix?

The strongest opportunities are likely to involve a specific container system, prefilled device, stability profile, or manufacturing process. Broad claims to calcium gluconate in sodium chloride are likely to face substantial prior-art challenges.

Why are ready-to-use calcium gluconate bags commercially attractive?

They reduce pharmacy preparation, support emergency availability, limit manipulation of sterile products, simplify inventory, and can improve dosing consistency. Their value is greatest where hospitals face sterile-compounding labor constraints or injectable supply shortages.

References

1. U.S. Food and Drug Administration. (n.d.). Calcium gluconate injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Parts 210 and 211: Current good manufacturing practice for drugs. https://www.ecfr.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. United States Pharmacopeia. (2024). USP-NF general chapters for sterile preparations, injections, and pharmaceutical packaging. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/